The Medwatch panel: Should all trial data be disclosed?
The CEO of Lundbeck says that a general openness about data from clinical studies could increase the risk of unnecessary confusion and uncertainty among patients and health care professionals. See what the rest of the members of this month’s Medwatch panel had to say about one of the hottest topics in the EU parliament just now.
by Louise Reseke & Henrik Tüchsen
June this year the EU parliament held a conference about the need for full access to results of human trials from the pharmaceutical industry.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
The Medwatch panel: Top-execs warn against quick fix
For abonnenter
